JCB, Volume 15, Number 4, 2009 Editorial Vol.15 No. 4 (2009) Intellectual property and biotechnology innovation: To protect or not protect? Yali Friedman The intellectual property protection differences between countries is a contentious issue. Countries with strong innovation systems (technology producers) often favor stron Commentary Vol.15 No. 4 (2009) The correlation between medical tourism and biotechnology David G Vequist IV   Commentary Vol.15 No. 4 (2009) The VC manifesto: Special pleading for a damaged cause: Commentary on Simon Witney interview William Bains   Article Vol.15 No. 4 (2009) Innovate America: The Technology Innovation Program at NIST Andrew S Klein 9 August 2007, the US Congress established the Technology Innovation Program (TIP) through the America COMPETES Act, a comprehensive strategy to keep the United States, Article Vol.15 No. 4 (2009) Valuation of complex license contracts Ralph Villiger Licensing is an important business model within the drug development industry. Recently license contracts have become extremely complex, including sublicensing, co-deve Article Vol.15 No. 4 (2009) How can pharmaceutical and biotechnology companies maintain a high profitability? Klaus J Nickisch Biotechnology investors are increasingly concerned about taking the risk of investing in the development of innovative drugs, and pharmaceutical companies are worried a Article Vol.15 No. 4 (2009) Multiyear patterns regarding the relative availability of venture capital for the US biotechnology industry J Leslie Glick Venture capital (VC) funding of US biotechnology companies was analysed relative to total VC investments placed in US companies from 1995 to 2007. During those years, e Article Vol.15 No. 4 (2009) Building biotechnology teams: Personality does matter Anne S York Our study describes a naturally occurring experiment exploring linkages between interdisciplinary team outcomes and personality dimensions, general mental ability, and Article Vol.15 No. 4 (2009) Beacon Sciences: Commercialisation from biothreat detection to beauty enhancement Rob Hanes Beacon Sciences is an excellent example of how technology from an American university can be developed and commercialised resulting in applications across multiple indu Legal and Regulatory Updates Vol.15 No. 4 (2009) Legal and Regulatory Update Gerry Kamstra   Book Review Vol.15 No. 4 (2009) Book Review: Genomics & society: Legal, ethical and social dimensions Dominic Clark Genomics & society: Legal, ethical and social dimensions George Gaskell and Martin W Bauer (eds.)Earthscan Ltd, London, 2007, pape Book Review Vol.15 No. 4 (2009) Book Review: Commercialization of innovative technologies: Bringing good ideas to the marketplace Arlen D Meyers Commercialization of innovative technologies: Bringing good ideas to the marketplaceC Joseph Touhill, Gregory J Touhill and Thomas A O'RiordanJohn Wiley and Sons, Hoboken, N Book Review Vol.15 No. 4 (2009) Book Review: Biotech funding trends: Insights from entrepreneurs and investors J Leslie Glick Biotech funding trends: Insights from entrepreneurs and investorsAlexandra Carina GruberWILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2009, hardback, 210pp.,ISBN 97
